Day-of FDA Inspection Protocols for Gummy Supplement Facilities: What to Do When the Investigator Walks In

The First 30 Minutes: Managing Investigator Arrival at Your Gummy Facility

An FDA inspection under 21 CFR Part 111 does not come with a scheduled appointment. Investigators from the Office of Regulatory Affairs (ORA) can appear at your gummy supplement facility on any standard business day, and the way your team responds in the first 30 minutes will shape the entire inspection. Facility owners and QA managers who have rehearsed this scenario almost always perform better than those who have not — not because they hide anything, but because they project professionalism, maintain control of the narrative, and avoid the kind of off-the-cuff statements that create unnecessary observations.

The moment an FDA investigator presents their credentials — typically an FDA Form 482, Notice of Inspection — your front-line staff should know exactly what to do. Reception and production staff should never attempt to answer regulatory questions on their own. A single, designated escort should be notified immediately. That escort is almost always your QA Manager or Quality Director, and they should drop what they are doing and meet the investigator at the entrance. While the escort is being summoned, offer the investigator a place to sit, water, and a copy of your facility's organizational chart if one is immediately available. Do not leave the investigator unsupervised in any production or storage area.

Once your QA lead arrives, confirm the scope of the inspection. Ask the investigator directly: Is this a routine GMP surveillance inspection, a follow-up to a previous 483, or a for-cause inspection? You are entitled to know the scope. Routine inspections under 21 CFR Part 111 typically cover your gummy production documentation, personnel training records, raw material testing, batch records, and sanitation controls. For-cause inspections, often triggered by a consumer complaint or a market withdrawal, may have a narrower focus. Knowing the scope helps you prepare the right documents and assign the right subject matter experts to accompany the investigator.

Escorting Investigators Through Your Gummy Production Environment

Gummy supplement manufacturing environments present a unique set of conditions that FDA investigators are trained to evaluate. Your mogul system, depositing lines, cooking kettles, cooling tunnels, and coating pans all represent critical process steps where 21 CFR Part 111 GMP controls must be visibly in place. When an investigator asks to walk your production floor — and they will — your escort should know the purpose and GMP significance of every piece of equipment in the room.

Do not rush the investigator through your facility, and do not attempt to steer them away from areas that are active or in-process. If a batch of pectin-based gummies is in the depositing phase, let the investigator observe. What they want to see is that your operators are following written SOPs, that in-process checks are being documented in real time, and that critical parameters — cooking temperature, water activity targets, Brix levels — are being monitored and recorded. If your operators are doing their jobs correctly, an active production run is one of the best things an investigator can witness.

Pay particular attention to the following areas where gummy-specific GMP observations are most commonly generated:

• Raw material storage and quarantine: Gelatin, pectin, active ingredients, colorants, and flavors should all be stored in clearly labeled, segregated areas with quarantine and release status visibly indicated. Investigators routinely check whether released materials are physically separated from quarantined materials.
• Cooking and temperature control: Cooking step parameters — temperature, hold time, mixing speed — must be defined in the Master Manufacturing Record (MMR) and documented on the Batch Production Record (BPR) for every batch. Inconsistencies between the MMR and BPR are a common 483 observation at gummy facilities.
• Water activity monitoring: Gummy products are highly susceptible to microbial growth if water activity is not properly controlled. Investigators will ask to see your water activity specifications, your calibrated meter records, and how out-of-spec results trigger your CAPA system.
• Bloom strength records for gelatin: If you use animal-derived gelatin, bloom strength specifications should be defined in your raw material spec sheet and verified against the supplier's Certificate of Analysis (COA). If you conduct incoming bloom testing, show those records.
• Coating and finishing controls: If your gummies receive a wax coating, sugar sanding, or carnauba wax application, that step must be covered in your MMR with defined parameters and in-process documentation requirements.

Assign a second team member — typically a production supervisor — to accompany the escort and investigator on the floor walk. This person can answer operational questions without the QA manager needing to leave the investigator's side. Never send the investigator onto the production floor with only a production operator. That arrangement too often results in undocumented verbal admissions about process deviations, equipment issues, or training gaps.

Document Requests: What to Produce, How Fast, and What to Say When You Cannot

After the facility walkthrough, most FDA investigators will request a set of documents. At a gummy supplement facility operating under 21 CFR Part 111, common document requests include Master Manufacturing Records, Batch Production Records, laboratory testing records, finished product specifications, supplier qualification files, training records, deviation logs, and CAPA documentation. Having a document request log — a simple form where you record every document requested, when it was provided, and who received it — is a best practice that many facilities overlook.

Speed matters, but accuracy matters more. If the investigator asks for the batch records for your last five gummy production runs and you can retrieve them in 10 minutes, do so. If retrieval will take 45 minutes because your records system requires a QA sign-off before printing, explain that process calmly and provide a realistic time estimate. Do not hand over documents that you have not reviewed. Take a moment — even just two or three minutes — to confirm that the document you are providing is the correct revision, that it is fully completed, and that it does not contain handwritten corrections or cross-outs that lack the required dated initials required by 21 CFR Part 111.

If an investigator asks for a document that does not exist — for example, a written water activity testing SOP when you have been performing the test but never formalized the procedure — do not fabricate a document and do not make promises about when it will be completed. The correct response is: "We perform this control, but we do not currently have a formal written SOP for this procedure. That is something we will address." Acknowledging a gap honestly is far better than producing a freshly backdated document, which constitutes fraud and transforms a 483 observation into a potential criminal matter.

Keep copies of everything you provide. If the investigator photocopies or photographs your batch records, your labels, or your equipment logs, make a corresponding note in your document request log. At the end of each inspection day, your QA team should debrief and document what was reviewed, what was requested, what observations appear to be forming, and what corrective steps you can take while the inspection is still in progress.

The Closeout Meeting: Responding to Preliminary Observations Before the 483 Is Issued

At the conclusion of an FDA inspection, the investigator will conduct a closeout meeting — sometimes called an end-of-inspection conference — where they verbally summarize any observations they intend to include on the FDA Form 483. This meeting is one of the most strategically important moments of the entire inspection, and it is consistently underutilized by gummy supplement manufacturers.

The closeout meeting is not the time to be defensive, dismissive, or emotional. It is, however, an appropriate time to provide factual clarifications if the investigator has misunderstood a process, misread a record, or is citing a requirement that does not apply to your specific product category. For example, if an investigator notes that your gummy facility lacks a written heavy metals testing protocol for a particular raw material but your internal risk assessment documents that ingredient as low-risk and you have supporting rationale on file, this is the moment to present that document and walk through your reasoning.

Equally important: if an investigator raises an observation that you know is valid, acknowledge it. Tell the investigator that you have identified the same gap, describe the interim control you have already implemented or will implement immediately, and commit to a realistic corrective action timeline. Investigators are not evaluating whether your facility is perfect — they are evaluating whether your quality system is capable of identifying and correcting its own deficiencies. A facility that can demonstrate self-awareness and a functioning CAPA process is far more credible than one that argues every observation.

After the closeout meeting, the investigator will leave a signed copy of the FDA Form 483 if observations were recorded. Your 15-business-day response window begins at that moment. Document the investigator's departure time, collect all copies of documents left behind, and convene your QA and leadership team the same afternoon for a structured debrief. Assign a preliminary owner to each observation, identify whether any interim controls can be deployed in the next 48 to 72 hours, and begin drafting your formal 483 response immediately — do not wait until day 12.

For gummy supplement manufacturers, the most common 483 observations center on incomplete batch records, inadequate supplier qualification files, missing or non-specific finished product specifications, and gaps in water activity or moisture testing documentation. If your facility has received observations in any of these categories before, treat the closeout meeting as a second chance to demonstrate that your corrective actions from the prior inspection actually held. Repeat observations — particularly on water activity controls, bloom strength verification, or COA review procedures — signal to FDA that your CAPA system is not effective, and repeat observations are one of the primary triggers for escalation to a Warning Letter.

Building a facility culture where every team member understands what an FDA inspection looks like — and what their role is during one — is not a one-time exercise. GummyGMP recommends annual mock inspection walkthroughs, quarterly document readiness reviews, and monthly internal audits that specifically target the gummy-specific GMP controls your real investigator will evaluate. When the investigator does walk through your door, the goal is not to pass an inspection. The goal is to show them a quality system that was already working before they arrived.